|
|
Post by babaoriley on Jan 16, 2019 19:19:16 GMT -5
Seriously, all I can say is "we'll see." Gotta give this program some time to figure how much this helps. Could be a game changer - maybe get to my critical mass number. Other pharmas may not like what we're doing, potentially a business model they won't love. If so, then that, in and of itself, is reason to do it!
|
|
|
|
Post by itellthefuture777 on Jan 16, 2019 19:21:51 GMT -5
Seriously, all I can say is "we'll see." Gotta give this program some time to figure how much this helps. Could be a game changer - maybe get to my critical mass number. Other pharmas may not like what we're doing, potentially a business model they won't love. If so, then that, in and of itself, is reason to do it! cost less than a happy meal..BOOM! Premarket should be fun to watch.. |
|
|
|
Post by itellthefuture777 on Jan 16, 2019 19:30:10 GMT -5
“It is important for MannKind to help those whose lives depend on insulin, and, unfortunately, over 65,000 uninsured or under-insured patients today must pay cash for their insulin each month, typically at the pharmacy counter at prices that reflect the costs of the pharmaceutical distribution chain,” said Michael Castagna, Chief Executive Officer of MannKind. “Our new Afrezza Patient Direct Program enables us to streamline the numerous costs and inefficiencies that exist in today’s healthcare system, so we can pass along the savings directly for these patients. We want to be part of the solution for the future of healthcare and healthy living.” finance.yahoo.com/news/mannkind-announces-direct-purchase-insulin-213000718.html?.tsrc=applewf Mannkind commercials between questions at the over priced large pharma hearings...ohh..wouldnt that be awesome! |
|
|
|
Post by itellthefuture777 on Jan 16, 2019 19:32:43 GMT -5
Very proud to be a stock holder today..what an awesome company and leadership! $4 a day Insulin..Sooo freaking amazing! Making the world a better place-
|
|
|
|
Post by letitride on Jan 16, 2019 19:45:47 GMT -5
All I have to say is Thank You Mike for having a Set. Al couldnt have done it better. Go Mannkind!
|
|
|
|
Post by mannmade on Jan 16, 2019 19:59:56 GMT -5
While I like this plan the real next step will to put out the program previously mentioned which is a sustainable monthly direct cash payment program such as previously discussed w One Drop that allows for reasonable price to pwd/consumers and a fair profit to mnkd.
|
|
|
|
Post by goyocafe on Jan 16, 2019 20:00:23 GMT -5
What? And skip my morning macchiato? No thanks!  I can imagine...all the large pharma in the hearings on their high prices...and then Mannkind gets a mention by Congress...How is it..this 1% company has what appears to better outcomes..can sell insulin at $4 a day..I mean..lower hypos..no shot..free inhaler..no weight gain..why is your slower in and out insulins..so expensive? Ohhhhh! The reality of the $4 price is that it is not sustainable. If it garners Mannkind some short term press, great. But it is a promotional price that will cost the company money to run. I hope the pr benefits outweigh the costs. |
|
|
|
Post by sportsrancho on Jan 16, 2019 20:02:46 GMT -5
|
|
|
|
Post by cedafuntennis on Jan 16, 2019 20:13:18 GMT -5
Well, now there are only two weeks left and I can't find anything about the program. Not much time left to sign up 1,000 people. Is there a chance that the Direct Purchase Program will provide meaningful data to management on what effect pricing may have on adoption AND retention, which may lead to something more permanent? That and it may very well be the leading step into increased commercials presence and OneDrop. I just hope they replace that stupid "award winning" TV ad. |
|
|
|
Post by itellthefuture777 on Jan 16, 2019 20:37:43 GMT -5
I can imagine...all the large pharma in the hearings on their high prices...and then Mannkind gets a mention by Congress...How is it..this 1% company has what appears to better outcomes..can sell insulin at $4 a day..I mean..lower hypos..no shot..free inhaler..no weight gain..why is your slower in and out insulins..so expensive? Ohhhhh! The reality of the $4 price is that it is not sustainable. If it garners Mannkind some short term press, great. But it is a promotional price that will cost the company money to run. I hope the pr benefits outweigh the costs. actually...Mannkind cutout the inefficency in the supply chain..65k people x 4 a day is the calculated folks that pay cash..65k x 4 =260k a day..x 365.250 is $94,965,000 a year..$121.75 a month...Afrezza can be used by type 1 and type 2..the U.S. has 30,000,000 x $121.75 x 12 = $43,830,000,000 a year..Large Pharma has a probem..in the Prandial space...As I recall Al saying 72% of diabetics would only need Afrezza...just say'n They have a product with superior glycemic control..non inferior to..anything else..less hypo risk..better price point..than..anything on the Inhaled Prandial market..robotic factory..modular expandable..why are we at $1.39? Hell if I know the factory cost $300 million..the investment in Afeezza was what $3 billion..we're financed to 2020..commercials ...and my guess is a media storm is coming..that will let everyone know..about Afrezza..and Mannkind like..no other insulin company..and those companies are flat lining from 2014..but Mannkind is a "growth engine" and Mike just turned on the key! Long MNKD...Shorts should be in panic mode..I am okay with that and that is just the U.S...the prjection is 500,000,000 diabetics world wide by 2030 I dunno..I thought I heard Key opinion leaders saying "it's obvoius Afrezza halts progression" $1.39 a share..really? Lets see that script count 8 weeks from now..fasten seat belts..we have so many shorts to use for rocket fuel... |
|
|
|
Post by akemp3000 on Jan 16, 2019 20:42:12 GMT -5
Some have said there are many endos, pcps and others in the diabetic community that still wrongly think inhaled insulin is no longer available, is a niche drug, is too expensive or is just generally not going to succeed. The new DTC TV ad campaign combined with rising scripts and now the direct purchase program are an excellent step toward proving to the mainstream diabetic community that Afrezza is here to stay. Good job Mannkind.
|
|
|
|
Post by itellthefuture777 on Jan 16, 2019 21:04:26 GMT -5
|
|
|
|
Post by nylefty on Jan 16, 2019 21:35:21 GMT -5
MNKD - Getting a lot of questions from people about news after the bell regarding a new set of marketing initiatives announced by the company. I will be blunt - I have no idea about the unit economics associated with the initiatives, but sounds very good to me. I have no idea about ARPU - “as low as $4” generally means very few at $4, and for 12 months, then the step up? And what cost basis? No idea. (snip) I hope that's not the case this time. |
|
|
|
Post by longliner on Jan 16, 2019 22:00:46 GMT -5
I can imagine...all the large pharma in the hearings on their high prices...and then Mannkind gets a mention by Congress...How is it..this 1% company has what appears to better outcomes..can sell insulin at $4 a day..I mean..lower hypos..no shot..free inhaler..no weight gain..why is your slower in and out insulins..so expensive? Ohhhhh! The reality of the $4 price is that it is not sustainable. If it garners Mannkind some short term press, great. But it is a promotional price that will cost the company money to run. I hope the pr benefits outweigh the costs. Awareness |
|
|
|
Post by neil36 on Jan 16, 2019 22:05:45 GMT -5
How many years did Amazon get bashed for its laser focus on market share at the expense of short-term profits?
The timing is great here for grabbing attention while BP is on the ropes for insulin price-gouging.
|
|
